Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
341actual
Sites
214
Countries
Argentina, Australia, Belgium +24
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-03 | actual | When the study began enrolling |
| Primary completion | 2026-07-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-23 | estimated | The whole study's end, after follow-up |
| First posted | 2022-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma
- Non-Small-Cell Lung
Interventions
- Drug: Savolitinib — also filed as AZD6094, HMPL-504, volitinib
- Drug: Osimertinib — also filed as AZD9291, Tagrisso
- Drug: Pemetrexed — also filed as NAP
- Drug: Cisplatin — also filed as NAP
- Drug: Carboplatin — also filed as NAP
Primary outcome
what the primary-completion date above is the date OFProgression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib.
measured Approximately 36.5 months post first subject randomized
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed